Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities
Lupus · 2025-09 · 34 (10) · 1024-1028
DOI: 10.1177/09612033251361040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lupus, online erschienen am 12.07.2025. Verfasst von Alfonso Ragnar Torres Jimenez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Mexico City, Mexico. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objective
We present the clinical, laboratory, and treatment characteristics of patients diagnosed with primary antiphospholipid syndrome according to the 2023 ACR/EULAR APS classification criteria. Material and methods A retrospective study was conducted in patients under 18 years of age, diagnosed with primary antiphospholipid syndrome according to the 2023 ACR/EULAR classification criteria, at the General Hospital of the National Medical Center La Raza, Mexico, from January 2013 to January 2025. Data on clinical manifestations, laboratory, and treatment were collected.
Results
We present data from 40 patients, 22 female and 18 male, with a mean age at diagnosis of 12.8 years. The time to diagnosis was 15.4 weeks. Thrombosis occurred in 14 patients. Thrombocytopenia in 34. Autoimmune hemolytic anemia in 18, Fisher Evans syndrome in 17. Livedo in 33, skin ulcers in 2, and Raynaud’s phenomenon in 15. Epileptic seizures in 2 and chorea in 1. We did not find cardiac valvular involvement. Renal involvement was found in 4. Prolonged aPTT in 39 (97.5%), positive lupus anticoagulant in 39, positive anticardiolipin IgG in 32, positive anticardiolipin IgM in 18, anti-B2GPI IgG performed in 17 patients, positive in 15, anti-B2GPI IgM performed in 12, positive in 4. Treatment consisted of anticoagulation in 13 patients, antiplatelet agents in 29, steroids in 35 immunosuppressants in 33, and rituximab in 6. One patient died from an alveolar hemorrhage.
Conclusions
The 2023 ACR/EULAR APS criteria improve the classification of pediatric patients by including non-thrombotic criteria; however, there are other non-thrombotic manifestations that are common in children that should be taken into account in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Rheumatology, National Medical Center La Raza, IMSS, Mexico City, Mexico.
- Department of Pediatric Hematology, National Medical Center La Raza, IMSS, Mexico City, Mexico.
- Department of Pediatric Rheumatology, Hospital General de Mexico Dr Eduardo Liceaga, SSA, Mexico City, Mexico.
- Research Unit in Immunology and Infectology, National Medical Center La Raza, IMSS, Mexico City, Mexico.
ORCID-Profile: Alfonso Ragnar Torres Jimenez
Zitieren
APA
Torres Jimenez, A. R., Sanchez Jara, B., Cespedes Cruz, A. I., Ramirez Nova, V., Velazquez Cruz, A., Cortina Olvera, G. D. C., Bekker Méndez, V. C., & Guerra Castillo, F. X. (2025). Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities. Lupus, 34(10), 1024-1028. https://doi.org/10.1177/09612033251361040
Vancouver
Torres Jimenez AR, Sanchez Jara B, Cespedes Cruz AI, Ramirez Nova V, Velazquez Cruz A, Cortina Olvera GDC, et al. Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities. Lupus. 2025;34(10):1024-1028. doi:10.1177/09612033251361040
BibTeX
@article{TorresJimenez2025,
author = {Torres Jimenez, Alfonso Ragnar and Sanchez Jara, Berenice and Cespedes Cruz, Adriana Ivonne and Ramirez Nova, Virginia and Velazquez Cruz, Alejandra and Cortina Olvera, Guadalupe Del Consuelo and Bekker Méndez, Vilma Carolina and Guerra Castillo, Francisco Xavier},
title = {Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities},
journal = {Lupus},
year = {2025},
volume = {34},
number = {10},
pages = {1024--1028},
doi = {10.1177/09612033251361040}
}
EUVIMED